Sanofi genzyme

Sanofi Genzyme: A Global Leader in Specialty Care

Sanofi Genzyme is a global specialty care business unit of Sanofi, a leading pharmaceutical company that operates in more than 170 countries worldwide. The company's focus is on developing innovative therapies for rare diseases, rare blood disorders, neurology, immunology, and oncology.

With over three decades of experience in the biotechnology industry, Sanofi Genzyme has established itself as a leader in the field of specialty care. The company's mission is to improve the lives of patients with serious medical conditions by providing them with effective treatments that address their unique needs.

Rare Diseases

Sanofi Genzyme has made significant contributions to the treatment of rare diseases. These are conditions that affect fewer than 200,000 people in the United States or less than one person per 2,000 worldwide. Despite their rarity, there are over 7,000 known rare diseases affecting an estimated 400 million people globally.

The company's portfolio includes treatments for Gaucher disease and Fabry disease - two genetic disorders that affect enzyme function and can lead to severe health problems if left untreated. Sanofi Genzyme also offers therapies for Pompe disease - a neuromuscular disorder caused by an enzyme deficiency - and mucopolysaccharidosis type I (MPS I) - a metabolic disorder characterized by abnormal accumulation of complex carbohydrates.

Rare Blood Disorders

In addition to its work on rare diseases affecting organs and tissues throughout the body, Sanofi Genzyme also focuses on developing treatments for rare blood disorders such as hemophilia A and B. These are genetic conditions that impair blood clotting ability due to deficiencies or abnormalities in clotting factors VIII or IX respectively.

The company offers several products designed to replace these missing clotting factors including Eloctate® (antihemophilic factor Fc fusion protein) which provides extended protection against bleeding episodes compared with traditional factor replacement therapy.

Neurology

Sanofi Genzyme has developed several innovative therapies for neurological disorders such as multiple sclerosis (MS). MS is an autoimmune condition where immune cells attack myelin sheaths surrounding nerve fibers causing inflammation leading to symptoms like muscle weakness or spasticity among others.

The company's flagship product Aubagio® (teriflunomide) was approved by FDA back in September 2012 as oral medication used once daily treatment option indicated relapsing forms MS patients including those who have experienced first clinical episode suggestive demyelination need additional diagnostic evaluation before starting therapy .

Immunology

Immunological disorders occur when immune system malfunctions resulting either underactivity overactivity response foreign substances body’s own cells tissues . This can lead various autoimmune inflammatory conditions like rheumatoid arthritis psoriasis Crohn’s disease ulcerative colitis among others .

Sanofi genzymes’ immunology portfolio includes Kevzara®(sarilumab), Dupixent®(dupilumab), Lemtrada®(alemtuzumab), Thymoglobulin®, Mozobil®, Clolar®, Campath®, Myozyme®, Aldurazyme®, Fabrazyme® etc., which offer effective treatment options for various immunological indications .

Oncology

Cancer remains one most challenging areas medicine today despite advances diagnosis treatment options available . Sanofis’ oncology portfolio includes Jevtana ®(cabazitaxel), Taxotere ®(docetaxel), Eloxatin ®(oxaliplatin), Zaltrap ®(ziv-aflibercept) etc., which offer effective treatment options various types cancers including breast cancer prostate cancer colorectal cancer lung cancer ovarian cancer pancreatic cancer among others .

Conclusion

In conclusion , Sanofis’ genzyne division continues be at forefront innovation development novel therapeutics addressing unmet medical needs across range therapeutic areas . With strong commitment improving patient outcomes through research development cutting-edge technologies , it’s no wonder why they’re considered leaders field specialty care today .